The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes

Clinical Biochemistry

Volumn 48, Issue 18, 2015, Pages 1264-1267

  Bekpinar, S ^a   Yenidunya, G ^a   Gurdol, F ^a   Unlucerci, Y ^a   Aycan Ustyol, E ^a   Dinccag, N ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Albuminuria; Apoprotein M; Asymmetric dimethylarginine; Diabetic nephropathy; Sphingosine 1 phosphate; Symmetric dimethylarginine

Indexed keywords

6 N,N' DIMETHYLARGININE; ALBUMIN; ARGININE; N(G),N(G) DIMETHYLARGININE; SPHINGOSINE 1 PHOSPHATE; APOLIPOPROTEIN; APOM PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOCALIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHOLIPID; N,N'-DIMETHYLARGININE; N,N-DIMETHYLARGININE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY DISEASE; KIDNEY DYSFUNCTION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ALBUMINURIA; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; MIDDLE AGED; PATHOPHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ALBUMINURIA; APOLIPOPROTEINS; ARGININE; BIOLOGICAL TRANSPORT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; LIPOCALINS; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; SPHINGOSINE; TRIGLYCERIDES;

EID: 84949090223     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.08.001     Document Type: Article

References (34)

1. Satchell S.C., Tooke J.E. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?. Diabetologia 2008, 51:714-725.
2. Thuy A.V., Reimann C.M., Hemdan N.Y., Gräler M.H. Sphingosine 1-phosphate in blood: function, metabolism, and fate. Cell. Physiol. Biochem. 2014, 34:158-171.
3. McVerry B.J., Garcia J.G. Endothelial cell barrier regulation by sphingosine 1-phosphate. J. Cell. Biochem. 2004, 92:1075-1085.
4. McVerry B.J., Garcia J.G. In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. Cell. Signal. 2005, 17:131-139.
5. Mehta D., Malik A.B. Signaling mechanisms regulating endothelial permeability. Physiol. Rev. 2006, 86:279-367.
6. Jernigan P.L., Makley A.T., Hoehn R.S., Edwards M.J., Pritts T.A. The role of sphingolipids in endothelial barrier function. Biol. Chem. 2015, 396:681-691.
7. Camerer E., Regard J.B., Cornelissen I., Srinivasan Y., Duong D.N., Palmer D., Pham T.H., Wong J.S., Pappu R., Coughlin S.R. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J. Clin. Invest. 2009, 119:1871-1879.
8. Obinata H., Hla T. Sphingosine 1-phosphate in coagulation and inflammation. Semin. Immunopathol. 2012, 34:73-91.
9. Bode C., Sensken S.C., Peest U., Beutel G., Thol F., Levkau B., et al. Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J. Cell. Biochem. 2010, 109:1232-1243.
10. Aoki S., Yatomi Y., Ohta M., Osada M., Kazama F., Satoh K., et al. Sphingosine 1-phosphate-related metabolism in the blood vessel. J. Biochem. 2005, 138:47-55.
11. Argraves K.M., Argraves W.S. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J. Lipid Res. 2007, 48:2325-2333.
12. Adamson R.H., Clark J.F., Radeva M., Kheirolomoom A., Ferrara K.W., Curry F.E. Albumin modulates S1P delivery from red blood cells in perfused microvessels: mechanism of the protein effect. Am. J. Physiol. Heart Circ. Physiol. 2014, 306:H1011-H1017.
13. Nofer J.R., van der Giet M., Tölle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 2004, 113:569-581.
14. Argraves K.M., Gazzolo P.J., Groh E.M., Wilkerson B.A., Matsuura B.S., Twal W.O., et al. High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J. Biol. Chem. 2008, 283:25074-25081.
15. Christoffersen C., Obinata H., Kumaraswamy S.B., Galvani S., Ahnström J., Sevvana M., et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9613-9618.
16. Awad A.S., Rouse M.D., Khutsishvili K., Huang L., Bolton W.K., Lynch K.R., et al. Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. Kidney Int. 2011, 79:1090-1098.
17. Xu H., Jin Y., Ni H., Hu S., Zhang Q. Sphingosine-1-phosphate receptor agonist, FTY720, restores coronary flow reserve in diabetic rats. Circ. J. 2014, 78:2979-2986.
18. Tong X., Lv P., Mathew A.V., Liu D., Niu C., Wang Y., et al. The compensatory enrichment of sphingosine-1-phosphate harbored on glycated high-density lipoprotein restores endothelial protective function in type 2 diabetes mellitus. Cardiovasc. Diabetol. 2014, 13:82.
19. Abu El-Asrar A.M., Nawaz M.I., Mohammad G., Siddiquei M.M., Alam K., Mousa A., et al. Expression of bioactive lysophospholipids and processing enzymes in the vitreous from patients with proliferative diabetic retinopathy. Lipids Health Dis. 2014, 13:187.
20. Siroen M.P., Teerlink T., Nijveldt R.J., Prins H.A., Richir M.C., van Leeuwen P.A. The clinical significance of asymmetric dimethylarginine. Annu. Rev. Nutr. 2006, 26:203-228.
21. Cavusoglu E., Ruwende C., Chopra V., Poludasu S., Yanamadala S., Frishman W.H., et al. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis 2010, 210:226-231.
22. Strobel J., Mieth M., Endress B., Auge D., König J., Fromm M.F., et al. Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1). J. Mol. Cell. Cardiol. 2012, 53:392-400.
23. Kielstein J.T., Salpeter S.R., Bode-Boeger S.M., Cooke J.P., Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function-a meta-analysis. Nephrol. Dial. Transplant. 2006, 21:2446-2451.
24. Fliser D., Kronenberg F., Kielstein J.T., Morath C., Bode-Böger S.M., Haller H., et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J. Am. Soc. Nephrol. 2005, 16:2456-2461.
25. Hanai K., Babazono T., Nyumura I., Toya K., Tanaka N., Tanaka M., et al. Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol. Dial. Transplant. 2009, 24:1884-1888.
26. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999, 130:461-470.
27. Teerlink T. Determination of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in biological samples by HPLC. Methods Mol. Med. 2005, 108:263-274.
28. Doumas B.T., Watson W.A., Biggs H.G. Albumin standards and the measurement of serum albumin with bromcresol green. Clin. Chim. Acta 1971, 31:87-96.
29. Atzler D., Schwedhelm E., Nauck M., Ittermann T., Böger R.H., Friedrich N. Serum reference intervals of homoarginine, ADMA, and SDMA in the study of health in Pomerania. Clin. Chem. Lab. Med. 2014, 52:1835-1842.
30. Wilkerson B.A., Grass G.D., Wing S.B., Argraves W.S., Argraves K.M. Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. J. Biol. Chem. 2012, 287:44645-44653.
31. Ohkawa R., Nakamura K., Okubo S., Hosogaya S., Ozaki Y., Tozuka M., et al. Plasma sphingosine-1-phosphate measurement in healthy subjects: close correlation with red blood cell parameters. Ann. Clin. Biochem. 2008, 45:356-363.
32. Godfrey L., Yamada-Fowler N., Smith J., Thornalley P.J., Rabbani N. Arginine-directed glycation and decreased HDL plasma concentration and functionality. Nutr. Diabetes 2014, 4:e134.
33. Kurano M., Tsukamoto K., Ohkawa R., Hara M., Iino J., Kageyama Y., Ikeda H., Yatomi Y. Liver involvement in sphingosine 1-phosphate dynamism revealed by adenoviral hepatic overexpression of apolipoprotein M. Atherosclerosis 2013, 229(1):102-109.
34. Shroff R., Speer T., Colin S., Charakida M., Zewinger S., Staels B., et al. HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype. J. Am. Soc. Nephrol. 2014, 25:2658-2668.